Biosyent Inc (TSXV:RX)
C$ 11 -0.15 (-1.35%) Market Cap: 127.46 Mil Enterprise Value: 111.19 Mil PE Ratio: 18.36 PB Ratio: 3.60 GF Score: 96/100

Q2 2023 Biosyent Inc Earnings Call Transcript

Aug 22, 2023 / NTS GMT
Release Date Price: C$7.6
RenÃ;C. Goehrum
BioSyent Inc. - Chairman, CEO & President

© -

Hello and welcome to the BioSyent Inc. Q2 and First Half 2023 Results Presentation. My name is René Goehrum and I'm the President and CEO of the company. I want to bring your attention to our disclaimer regarding forward-looking statements and we'll dive into the presentation looking first at our sales results in the quarter.

So this is for the period ending June 30, 2023, on a quarter basis and on a half basis. You can see our Canadian Pharmaceutical business performed well at 23% growth, reaching just over $7.7 million and on a 6-month basis for the first half, up 12%. The drivers of this performance could be characterized across the portfolio and we had a strong performance on FeraMAX at 25% up for the quarter, Tibella at 49%, Combogesic and RepaGyn showing a slightly less growth. And then looking at those brands on a 6-month basis, you can see FeraMAX up 13%, Tibella up 44%. Some decline in the Combogesic business that was notable from the first quarter. Obviously, we made up for some of that ground in the second

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot